Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab added to lenalidomide and dexamethasone for newly diagnosed multiple myeloma
ACTRN12619000362190Phase 2Active, not recruiting
- Sponsor
- Australasian Myeloma Research Consortium
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Australasian Myeloma Research Consortium. Primary endpoint: Partial response or better after additional ILd therapy. Started Jun 2019; status: active, not recruiting.
02
Drugs
isatuximablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12619000362190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000362190.